ProPhase Labs to Present at the Planet MicroCap Showcase 2022 on Wednesday, May 4, 2022
ProPhase Labs, Inc. (NASDAQ: PRPH) announced that Chairman and CEO Ted Karkus will present a corporate overview at the Planet MicroCap Showcase 2022 on May 4, 2022, at 1:30 PM EST. The presentation will be accessible through a webcast link provided in the announcement.
ProPhase Labs focuses on diagnostics and genomics, offering services like whole genome sequencing and COVID-19 testing through its CLIA-certified laboratories. The company aims to expand its testing capabilities globally and continues to pursue strategic investments.
- None.
- None.
Garden City, NY, April 27, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified diagnostics and genomics company, today announced that Chairman and CEO Ted Karkus will present a corporate overview at the Planet MicroCap Showcase 2022 on Wednesday, May 4, 2022 at 1:30 PM EST.
To access the presentation, please use the following information:
Planet MicroCap Showcase 2022
Date: Wednesday, May 4, 2022
Time: 1:30 PM Eastern Time (10:30 AM Pacific Time)
Webcast: https://www.webcaster4.com/Webcast/Page/2862/45058
The Planet MicroCap Showcase 2022 website is available here: https://planetmicrocapshowcase.com/
All company presentation “webcasts” will be available directly on the conference event platform on this link under the tab “Agenda”: https://planetmicrocapshowcase.com/agenda
About ProPhase Labs
ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase”) is a diversified diagnostics and genomics company that seeks to leverage its CLIA lab services to provide whole genome sequencing and research direct to consumers and build a genomics data base to be used for further research. The Company continues to provide traditional CLIA molecular laboratory services, including COVID-19 testing.
ProPhase Diagnostics, Inc., a wholly-owned subsidiary of ProPhase, offers a broad array of clinical diagnostic and testing services at its CLIA certified laboratories including state-of-the-art polymerase chain reaction (PCR) testing for SARS-CoV-2 (COVID-19). Critical to COVID-19 testing, ProPhase Diagnostics provides fast turnaround times for results. ProPhase Diagnostics also offers best-in-class rapid antigen and antibody/immunity tests to broaden its COVID-19 testing beyond RT-PCR testing.
ProPhase Precision Medicine, Inc., a wholly-owned subsidiary of ProPhase, focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA. The data obtained from genomic testing can help to identify inherited disorders and tendencies, help predict disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression.
ProPhase Global Healthcare, Inc., a subsidiary of ProPhase, was formed to seek to expand the Company’s SARS-CoV-2 (COVID-19) testing into other countries and to pursue additional healthcare-related initiatives.
ProPhase has decades of experience researching, developing, manufacturing, distributing, marketing, and selling OTC consumer healthcare products and dietary supplements under the TK Supplements® brand and Phamaloz contract manufacturing subsidiary.
ProPhase actively pursues strategic investments and acquisition opportunities for other companies, technologies, and products. For more information, visit www.ProPhaseLabs.com.
Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
267-880-1111
investorrelations@prophaselabs.com
Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman
514-939-3989
Jboidman@renmarkfinancial.com
FAQ
When is ProPhase Labs' presentation at the Planet MicroCap Showcase 2022?
Where can I access ProPhase Labs' presentation for the Planet MicroCap Showcase 2022?
What is the focus of ProPhase Labs, Inc.?
What are the main services offered by ProPhase Diagnostics, Inc.?
What is the stock symbol for ProPhase Labs?
